Telix Pharmaceuticals Ltd Stock: price and insider trades · United States
1 insider bought €17k of shares over the last 90 days, the latest by Smith Darren Charlton, filed 14 Sept 2026.
Telix Pharmaceuticals Ltd: what insiders have been doing
Telix Pharmaceuticals Ltd, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 8 November 2025 and 8 November 2026, 2 insiders published 3 filings.
Only purchases show up on the open market, 2 purchases in all worth €444k, filed by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 finance chief and 1 chief executive. One trade stands out by size: a purchase of €426k from Behrenbruch Christian, disclosed on 6 May 2026, or 0.013% of market capitalisation.
The most recent open-market purchase was published on 14 September 2026, 55 days ago. Filings reach the SEC (Form 4) feed a median of 7 days after the trade. Section 16 rules allow two business days to file each Form 4.
With 3 filings in twelve months, the company is quieter than the median of 19 filings across the 5,811 companies we follow on the same exchange. Looking back to 2026, when coverage begins, insiders filed 2 purchases and no sales. The 20-F for the year ended 31 December 2025 shows 803.8 m USD of revenue and -7.1 m USD of net income.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -0.8%Entry US$10.66 · Close 15 Oct 2026 US$10.57
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Telix Pharmaceuticals Ltd Strong Buy (bullish), based on 5 analysts. Average price target: US$20.58.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 2,071 shares@ US$9.6560.0005% mcap100.0% of flowOrdinary SharesSEC:0001628280-26-061944:0Canonical exit: 6 Dec 2026 (T+90)
- 34,500 shares@ US$14.480.013% mcap100.0% of flowOrdinary SharesSEC:0001628280-26-031608:0Canonical exit: 27 Jul 2026 (T+90)
- 1,111 shares0Ordinary SharesSEC:0001628280-26-022909:0
3 of 3 declarations
About Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd (NASDAQ: TLX) is a global biopharmaceutical company focused on radiopharmaceuticals and precision oncology. Although the company is headquartered in Melbourne, Australia, it maintains meaningful operations in the United States and trades on the NASDAQ market in the United States, making it relevant for international investors seeking exposure to a fast-growing segment of nuclear medicine. Telix describes itself as a therapeutics-led company, combining diagnostic and therapeutic radiopharmaceuticals with associated medical technologies to support the cancer care pathway. ([telixpharma.com](https://telixpharma.com/our-company/?utm_source=openai))
Telix was built around a strategy that centers on targeted cancer imaging and therapy, particularly in oncology areas where there remains substantial unmet medical need. Its operational footprint spans the United States, Europe, and Japan, with offices or activities in Belgium and Switzerland as well as in the U.S. That geographic spread is important because it supports clinical development, manufacturing, regulatory execution, and commercial rollout across major healthcare markets. ([telixpharma.com](https://telixpharma.com/our-company/?utm_source=openai))
Read moreShow less
The company’s business model is organized around two main pillars. First, its Precision Medicine business develops and commercializes imaging agents, with a strong focus on urologic oncology, especially prostate and kidney cancer. Second, Telix is advancing a therapeutics pipeline aimed at broader oncology indications, while also building out medtech capabilities through surgical solutions and digital products that complement its cancer portfolio. This combination gives Telix a more integrated profile than a pure-play diagnostic company. ([telixpharma.com](https://telixpharma.com/our-company/?utm_source=openai))
In competitive terms, Telix positions itself at the intersection of radiology, oncology, and precision medicine. Its lead commercial product, Gozellix®, is a next-generation PSMA-PET imaging agent for prostate cancer that became commercially available in the United States in 2025. The company has also been advancing multiple late-stage therapeutic programs and broader platform assets, which gives it optionality beyond its current commercial base. In addition, Telix announced a strategic collaboration with Varian, a Siemens Healthineers company, to explore combining Telix’s theranostic products with external beam radiation therapy. ([ir.telixpharma.com](https://ir.telixpharma.com/news-releases/news-release-details/telix-launches-new-prostate-cancer-imaging-agent-gozellix-us?utm_source=openai))
Recent operating updates suggest that Telix is moving through a period of strong commercial acceleration. For FY 2025, the company reported approximately US$804 million in revenue, up about 56% year over year, driven by its precision medicine franchise and the U.S. launch of Gozellix. Telix also continued to invest heavily in R&D and commercial infrastructure, while progressing clinical programs such as prostate cancer and bone metastases studies. For investors, this makes Telix a growth-oriented radiopharmaceutical company listed on the NASDAQ in the United States, with a mix of commercial execution, pipeline upside, and international expansion potential. ([ir.telixpharma.com](https://ir.telixpharma.com/news-releases/news-release-details/fy-2025-results-strong-commercial-growth-focused-pipeline?utm_source=openai))
